Zentalis Pharmaceuticals Inc Dossier - Source-backed chat

Zentalis Pharmaceuticals Inc

ZNTLNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.60

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.77Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $262.2M

Enterprise Value $276.1M

Shares Outstanding 94.7M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Zentalis Pharmaceuticals is a clinical-stage oncology innovator advancing its lead asset, azenosertib, a potentially first-in-class and best-in-class oral WEE1 inhibitor. The company is executing a highly targeted, biomarker-driven strategy focusing on Cyclin E1-positive platinum-resistant ovarian cancer (PROC), which represents approximately 50% of the PROC patient population. With the selection of the pivotal 400mg QD 5:2 monotherapy dose, the initiation of the Phase 3 ASPENOVA confirmatory trial, and a robust cash runway extending into late 2027, Zentalis is well-positioned to reach its critical year-end 2026 DENALI Part 2 topline readout, which could support an accelerated approval pathway.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$6.67

High · most bullish analyst$10.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.62

The DENALI Part 2 trial yields disappointing efficacy or reveals safety concerns (such as high-grade adverse events or high patient discontinuation rates), delaying or invalidating the accelerated approval pathway. Slower-than-expected enrollment in the ASPENOVA trial extends the development timeline, forcing the company to raise capital under unfavorable market conditions and diluting existing shareholders.

Base CaseCentral scenario

$5.50

Azenosertib demonstrates solid efficacy in Cyclin E1-positive PROC during the DENALI Part 2 readout by year-end 2026, aligning with historical Phase 1b/2 data. The FDA remains receptive to the accelerated approval pathway, and the confirmatory ASPENOVA Phase 3 trial progresses on schedule. The company's cash runway into late 2027 is sufficient to achieve these key clinical milestones without immediate dilutive financing.

Bull CaseUpside scenario

$10.00

The DENALI Part 2 trial meets its primary endpoints with a highly differentiated objective response rate (ORR) and a manageable safety profile, paving the way for accelerated FDA approval. Concurrently, the Phase 3 ASPENOVA trial enrolls rapidly, and combination trials (such as the MUIR trial with paclitaxel) demonstrate strong synergy, expanding azenosertib's addressable market into earlier lines of therapy and other solid tumors.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class and best-in-class potential for lead asset azenosertib as an oral WEE1 inhibitor.
Biomarker-driven approach targeting Cyclin E1-positive PROC, addressing a high unmet medical need in ~50% of PROC patients.
Strong cash position of $211.8 million as of March 31, 2026, providing an operational runway into late 2027.
Clear regulatory alignment with the FDA, utilizing the Phase 2 DENALI trial for accelerated approval and Phase 3 ASPENOVA as the confirmatory study.

Key Investment Risks

High clinical development risk concentrated heavily on a single lead asset (azenosertib).
Potential for high patient discontinuation rates due to adverse events or voluntary withdrawals in clinical trials.
Regulatory risks associated with companion diagnostic validation for Cyclin E1 overexpression.

Thesis Invalidation Triggers

Failure of DENALI Part 2 to meet its target efficacy endpoints or showing an unfavorable safety profile by year-end 2026.
FDA rejection of the accelerated approval pathway based on the DENALI trial design or data.
Severe clinical holds or safety halts imposed on the azenosertib clinical program.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.